News for Recursion Pharmaceuticals, Inc. (RXRX)

Shares of Recursion Pharmaceuticals (RXRX) experienced a significant drop of 7.05%, closing at $6.135. The decline was attributed to broader market concerns ove

Fiserv recently completed its acquisition of Payfare Inc. On

Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX.

The term "game-changing" is overused for too many up-and-coming companies, but in this case, the description fits.

On Thursday, March 6, 2025 Ark Invest made significant trades in Tempus AI and GitLab, increasing its tech and AI exposure after their earnings reports, while also adjusting positions in other stocks.

We recently published an article titled Trade Tensions Weigh Heavily on 10 Stocks. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.

Revenue: $83 million in 2024 on a pro forma basis.Cash Balance: Over $600 million, providing runway into 2027.Milestone Payments: $45 million from Sanofi and R

Feb 28, 2025 / 01:30PM GMTChristopher Gibson - Recursion Pharmaceuticals Inc - Chief Executive Officer, Director Welcome everybody to Recursion's Learning Skull

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call Transcript February 28, 2025Recursion Pharmaceuticals, Inc. misses on earnings expectations.

Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS.

Recursion Pharmaceuticals Inc showcases a robust drug discovery platform with significant clinical advancements.Strategic partnerships and proprietary technolo

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ETCompany ParticipantsChris Gibson - Co-Founder...

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -47.22% and 84.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals Inc (RXRX), a leading clinical-stage TechBio company, announced significant business updates and financial results for the fourth quar

On Tuesday, Cathie Wood-led Ark Invest made some significant trades, most notably buying into Tempus AI Inc. (NASDAQ:TEM) and Coinbase Global Inc.

Investors are continuing to assess the impact of new LLMs in the AI industry. X.

On Tuesday, Recursion Pharmaceuticals stock saw its Relative Strength Rating rising into the 90-plus percentile with an improvement to 92,

U.S. stocks were lower, with the Dow Jones falling around 100 points on Tuesday. Shares of Watsco Inc WSO rose sharply during Tuesday's session after the compa...